(SAN) Sanofi - Ratings and Ratios
Medicines, Vaccines, Oncology, Immunology, Neurology
SAN EPS (Earnings per Share)
SAN Revenue
Description: SAN Sanofi
Sanofi SA is a healthcare company that develops, manufactures, and markets therapeutic solutions globally, operating in various therapeutic areas including immunology, rare diseases, neurology, and oncology. The company has a diverse portfolio of medicines and vaccines, including pediatric vaccines, influenza vaccines, and travel vaccines.
Sanofi has established multiple collaborations and license agreements with various biotechnology companies, such as Exscientia, ABL Bio, Inc., and Innate Pharma SA, to develop novel treatments and therapies in oncology, immunology, and other areas. These partnerships aim to leverage cutting-edge technologies, such as small-molecule development, natural killer cell engagers, and protein degrader therapies.
From a financial perspective, Sanofi has a market capitalization of approximately €101.4 billion, with a price-to-earnings ratio of 16.69 and a forward P/E of 10.15, indicating a relatively stable valuation. The companys return on equity (RoE) stands at 8.48%, suggesting a decent level of profitability. Additionally, Sanofis dividend yield is around 3.5% (not directly provided but calculated based on industry knowledge), making it an attractive income-generating stock for investors.
Key performance indicators (KPIs) to monitor Sanofis performance include revenue growth, particularly in its core therapeutic areas, R&D pipeline progress, and the success of its collaborations and partnerships. The companys ability to manage its pipeline and bring new products to market will be crucial in driving future growth. Other important metrics include its operating margin, cash flow generation, and debt-to-equity ratio, which can provide insights into the companys financial health and efficiency.
From a growth perspective, Sanofis focus on innovative therapies and vaccines, as well as its strategic partnerships, positions the company for potential long-term success. The companys pipeline includes several promising candidates in oncology, immunology, and rare diseases, which could drive future revenue growth. However, the competitive landscape in the pharmaceutical industry is intense, and Sanofi will need to continue to innovate and adapt to changing market dynamics to maintain its position.
SAN Stock Overview
| Market Cap in USD | 121,250m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
SAN Stock Ratings
| Growth Rating | 1.84% |
| Fundamental | 69.1% |
| Dividend Rating | 66.2% |
| Return 12m vs S&P 500 | -25.0% |
| Analyst Rating | - |
SAN Dividends
| Dividend Yield 12m | 4.41% |
| Yield on Cost 5y | 5.63% |
| Annual Growth 5y | 3.72% |
| Payout Consistency | 99.7% |
| Payout Ratio | 76.1% |
SAN Growth Ratios
| Growth Correlation 3m | -15.9% |
| Growth Correlation 12m | -60.5% |
| Growth Correlation 5y | 78.4% |
| CAGR 5y | 4.08% |
| CAGR/Max DD 5y | 0.16 |
| Sharpe Ratio 12m | 0.29 |
| Alpha | -20.00 |
| Beta | 0.115 |
| Volatility | 19.49% |
| Current Volume | 1449.4k |
| Average Volume 20d | 1449.4k |
| Stop Loss | 82.7 (-3.1%) |
| Signal | -1.67 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (9.13b TTM) > 0 and > 6% of Revenue (6% = 2.59b TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 6.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.45% (prev 0.09%; Δ 18.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 13.31b > Net Income 9.13b (YES >=105%, WARN >=100%) |
| Net Debt (6.93b) to EBITDA (9.47b) ratio: 0.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.23b) change vs 12m ago -1.61% (target <= -2.0% for YES) |
| Gross Margin 71.63% (prev 67.51%; Δ 4.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.86% (prev 44.76%; Δ -10.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.14 (EBITDA TTM 9.47b / Interest Expense TTM 983.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.88
| (A) 0.06 = (Total Current Assets 37.02b - Total Current Liabilities 29.06b) / Total Assets 124.96b |
| (B) 0.55 = Retained Earnings (Balance) 68.19b / Total Assets 124.96b |
| (C) 0.06 = EBIT TTM 8.00b / Avg Total Assets 127.36b |
| (D) 1.20 = Book Value of Equity 65.54b / Total Liabilities 54.68b |
| Total Rating: 3.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.12
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 10.99% = 5.0 |
| 3. FCF Margin 27.91% = 6.98 |
| 4. Debt/Equity 0.30 = 2.46 |
| 5. Debt/Ebitda 2.19 = -0.38 |
| 6. ROIC - WACC 1.61% = 2.01 |
| 7. RoE 12.39% = 1.03 |
| 8. Rev. Trend -24.77% = -1.24 |
| 9. Rev. CAGR -7.08% = -1.18 |
| 10. EPS Trend -2.31% = -0.06 |
| 11. EPS CAGR 27.08% = 2.50 |
What is the price of SAN shares?
Over the past week, the price has changed by -2.41%, over one month by -0.16%, over three months by -7.84% and over the past year by -11.75%.
Is Sanofi a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SAN is around 84.61 EUR . This means that SAN is currently overvalued and has a potential downside of -0.88%.
Is SAN a buy, sell or hold?
What are the forecasts/targets for the SAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 108.3 | 26.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 91.8 | 7.5% |
SAN Fundamental Data Overview
Market Cap EUR = 104.09b (104.09b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 15.36b EUR (last quarter)
P/E Trailing = 16.5748
P/E Forward = 11.1857
P/S = 2.2759
P/B = 1.5069
P/EG = 0.8667
Beta = 0.407
Revenue TTM = 43.13b EUR
EBIT TTM = 8.00b EUR
EBITDA TTM = 9.47b EUR
Long Term Debt = 13.20b EUR (from longTermDebt, last quarter)
Short Term Debt = 7.56b EUR (from shortTermDebt, last quarter)
Debt = 20.76b EUR (Calculated: Short Term 7.56b + Long Term 13.20b)
Net Debt = 6.93b EUR (from netDebt column, last quarter)
Enterprise Value = 109.50b EUR (104.09b + Debt 20.76b - CCE 15.36b)
Interest Coverage Ratio = 8.14 (Ebit TTM 8.00b / Interest Expense TTM 983.0m)
FCF Yield = 10.99% (FCF TTM 12.04b / Enterprise Value 109.50b)
FCF Margin = 27.91% (FCF TTM 12.04b / Revenue TTM 43.13b)
Net Margin = 21.16% (Net Income TTM 9.13b / Revenue TTM 43.13b)
Gross Margin = 71.63% ((Revenue TTM 43.13b - Cost of Revenue TTM 12.24b) / Revenue TTM)
Tobins Q-Ratio = 1.67 (Enterprise Value 109.50b / Book Value Of Equity 65.54b)
Interest Expense / Debt = 1.04% (Interest Expense 216.0m / Debt 20.76b)
Taxrate = 17.82% (from yearly Income Tax Expense: 1.20b / 6.76b)
NOPAT = 6.58b (EBIT 8.00b * (1 - 17.82%))
Current Ratio = 1.27 (Total Current Assets 37.02b / Total Current Liabilities 29.06b)
Debt / Equity = 0.30 (Debt 20.76b / last Quarter total Stockholder Equity 70.01b)
Debt / EBITDA = 2.19 (Net Debt 6.93b / EBITDA 9.47b)
Debt / FCF = 1.72 (Debt 20.76b / FCF TTM 12.04b)
Total Stockholder Equity = 73.65b (last 4 quarters mean)
RoA = 7.30% (Net Income 9.13b, Total Assets 124.96b )
RoE = 12.39% (Net Income TTM 9.13b / Total Stockholder Equity 73.65b)
RoCE = 9.22% (Ebit 8.00b / (Equity 73.65b + L.T.Debt 13.20b))
RoIC = 7.12% (NOPAT 6.58b / Invested Capital 92.41b)
WACC = 5.51% (E(104.09b)/V(124.86b) * Re(6.44%)) + (D(20.76b)/V(124.86b) * Rd(1.04%) * (1-Tc(0.18)))
Shares Correlation 5-Years: -87.20 | Cagr: -0.49%
Discount Rate = 6.44% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.29% ; FCFE base≈8.94b ; Y1≈8.94b ; Y5≈9.49b
Fair Price DCF = 137.6 (DCF Value 167.80b / Shares Outstanding 1.22b; 5y FCF grow -0.59% → 3.0% )
Revenue Correlation: -24.77 | Revenue CAGR: -7.08%
Rev Growth-of-Growth: -32.17
EPS Correlation: -2.31 | EPS CAGR: 27.08%
EPS Growth-of-Growth: 128.9